Jacome M, Wu Q, Chen J, Mohamed Z, Mokhtari S, Pina Y
Int J Mol Sci. 2025; 26(5).
PMID: 40076927
PMC: 11900073.
DOI: 10.3390/ijms26052307.
Steinestel K, Arndt A
Diagnostics (Basel). 2025; 15(5).
PMID: 40075878
PMC: 11899415.
DOI: 10.3390/diagnostics15050631.
Zhang H, Xia W, Zhang Y, Bao S, Zeng J, Li X
Front Oncol. 2025; 15:1474997.
PMID: 40071084
PMC: 11893432.
DOI: 10.3389/fonc.2025.1474997.
Voena C, Ambrogio C, Iannelli F, Chiarle R
Nat Rev Cancer. 2025; .
PMID: 40055571
DOI: 10.1038/s41568-025-00797-9.
Hou C, Song X, Chen H, Chang C, Lu J, Li C
Pathol Oncol Res. 2025; 31:1611964.
PMID: 40017673
PMC: 11864879.
DOI: 10.3389/pore.2025.1611964.
Cancer brain metastasis: molecular mechanisms and therapeutic strategies.
Lu Y, Huang Y, Zhu C, Li Z, Zhang B, Sheng H
Mol Biomed. 2025; 6(1):12.
PMID: 39998776
PMC: 11861501.
DOI: 10.1186/s43556-025-00251-0.
Non-small cell lung cancer and the tumor microenvironment: making headway from targeted therapies to advanced immunotherapy.
De Lucia A, Mazzotti L, Gaimari A, Zurlo M, Maltoni R, Cerchione C
Front Immunol. 2025; 16:1515748.
PMID: 39995659
PMC: 11847692.
DOI: 10.3389/fimmu.2025.1515748.
Combined BRAF G469A mutation and echinoderm microtubule associated protein like-4-anaplastic lymphoma kinase rearrangement with resistance: A case report and review of literature.
Guo X, Liu Y, Wang Y, Liu K, Ding H
World J Clin Oncol. 2025; 16(2):98812.
PMID: 39995561
PMC: 11686558.
DOI: 10.5306/wjco.v16.i2.98812.
Development of an ALK-positive Non-Small-Cell Lung Cancer in Vitro Tumor 3D Culture Model for Therapeutic Screening.
Berry M, Bland A, Major G, Ashton J
J Histochem Cytochem. 2025; 73(1-2):63-79.
PMID: 39991927
PMC: 11851580.
DOI: 10.1369/00221554251318435.
Synthesis and Antitumor Activity of 6-(2-Aminobenzo[]thiazol-5-yl) quinazolin-4(3)-one Derivatives.
Linghu A, Tang L, Li Q, Zhong T, Luo F, Zhao X
ACS Omega. 2025; 10(6):5686-5698.
PMID: 39989817
PMC: 11840607.
DOI: 10.1021/acsomega.4c08645.
Efficacy and safety of first-line PD-1/PD-L1 inhibitor in combination with CTLA-4 inhibitor in the treatment of patients with advanced non-small cell lung cancer: a systemic review and meta-analysis.
Zhao H, Huang S, Wu J, Lu Y, Zou Y, Zeng H
Front Immunol. 2025; 16:1515027.
PMID: 39981238
PMC: 11839650.
DOI: 10.3389/fimmu.2025.1515027.
gene editing using primary cells derived from Cas9-expressing pigs.
Kim S, No J, Lee S, Choi A, Hyung N, Lee J
J Anim Sci Technol. 2025; 67(1):179-192.
PMID: 39974782
PMC: 11833195.
DOI: 10.5187/jast.2024.e77.
[Research Progress of ALK Activation Pattern Changes and Targeted Therapy
in Advanced Lung Cancer].
Wei A, Jiang B, Huang Y, Liu M, Yan J, Zhao Y
Zhongguo Fei Ai Za Zhi. 2025; 27(12):940-946.
PMID: 39962849
PMC: 11839494.
DOI: 10.3779/j.issn.1009-3419.2024.102.45.
Detection of Overlooked Rare EGFR Mutations in Non-small Cell Lung Cancer Using Multigene Testing.
Shiraishi N, Takahama T, Sakai K, Tanaka K, Nakagawa Y, Kanemura H
Thorac Cancer. 2025; 16(3):e70007.
PMID: 39947926
PMC: 11825211.
DOI: 10.1111/1759-7714.70007.
Emerging Targeted Therapies in Non-Small-Cell Lung Cancer (NSCLC).
Mina S, Shanshal M, Leventakos K, Parikh K
Cancers (Basel). 2025; 17(3).
PMID: 39941723
PMC: 11816067.
DOI: 10.3390/cancers17030353.
FusOn-pLM: a fusion oncoprotein-specific language model via adjusted rate masking.
Vincoff S, Goel S, Kholina K, Pulugurta R, Vure P, Chatterjee P
Nat Commun. 2025; 16(1):1436.
PMID: 39920196
PMC: 11806025.
DOI: 10.1038/s41467-025-56745-6.
Small cell lung cancer with EML4-ALK fusion: report of a case responding to ALK TKI and literature review.
Wang M, Liu H, Zhang R, Li R, Qin X, Ning F
J Cancer Res Clin Oncol. 2025; 151(2):62.
PMID: 39909915
PMC: 11799027.
DOI: 10.1007/s00432-025-06091-3.
Patients outcomes in lung adenocarcinoma transforming to small-cell lung cancer after tyrosine kinase inhibitor therapy.
Wang S, Wang Y, Wu X, Yang L, Zhang X
World J Surg Oncol. 2025; 23(1):34.
PMID: 39893475
PMC: 11787757.
DOI: 10.1186/s12957-025-03687-4.
FDA-approved drugs featuring macrocycles or medium-sized rings.
Du Y, Semghouli A, Wang Q, Mei H, Kiss L, Baecker D
Arch Pharm (Weinheim). 2025; 358(1):e2400890.
PMID: 39865335
PMC: 11771699.
DOI: 10.1002/ardp.202400890.
Machine Learning for Lung Cancer Subtype Classification: Combining Clinical, Histopathological, and Biophysical Features.
Andrijanova A, Bugovecka L, Isajevs S, Erts D, Malinovskis U, Liepins A
Diagnostics (Basel). 2025; 15(2.
PMID: 39857011
PMC: 11764335.
DOI: 10.3390/diagnostics15020127.